NST provided quality review for a broad range of regulatory documents, including:
We were also contracted to provide medical writing and editorial support as well as general QX function for all regulatory submission documents.
"“I cannot praise the Niche team highly enough, having been a huge support from the outset – we quickly built up a great relationship, they are very supportive, responsive to all my emails and incredibly approachable and friendly. They have made it clear that they are always there when we need them."
NST began work with Adaptimmune in 2024, conducting a QC review of an IB update for uzatresgene autoleucel, one of Adaptimmune’s TCR-based therapies. NST went onto play a pivotal role with the team responsible for the delivery of Adaptimmune’s regulatory documents. Adaptimmune appreciated NST’s flexibility and range of skills, meaning assistance could be scaled to address any of their medical writing needs across a broad range of regulatory documents for their various development assets.
NST established clear lines of communication with the Adaptimmune team to enable close tracking of multiple documents across a variety of projects with ambitious timelines. All documents were delivered to the highest quality and according to the agreed timelines.
The FRAILOMIC initiative was an international research project aimed at improving the understanding, diagnosis, and.
read moreAstex employs its proprietary Pyramidâ„¢ platform to develop innovative therapies targeting challenging or.
read moreSynairgen is a UK-based biopharmaceutical company focused on developing innovative treatments for respiratory diseases,.
read moreThe British Society for Haematology (BSH), the UK’s largest haematology organisation, promotes excellence within the.
read moreA specialist pharmaceutical company dedicated to HIV medicines and research with an extensive portfolio of prescription.
read moreCleothena Enterprises Pty Ltd. is a forward-thinking biotechnology company focused on advancing innovative therapeutic.
read moreRecardio is a life science company that focuses on drug-based regenerative therapeutic modalities for treatments of.
read moreNabriva Therapeutics was incorporated as a spin-off from Sandoz GmbH Antibiotics Research Institute (ABRI) in Vienna..
read moreAssign’s business model relied on bespoke service providers like Niche to deliver essential aspects of their business.
read moreBioKinetic Europe was a fully integrated clinical research organisation with its own purpose-designed clinical.
read moreScandinavian Development Services Life Science was a leading consultancy in the Nordics with regards to regulatory.
read moreGet our latest news and publications
Sign up to our news letterSocial
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
